Our Team


Postdoctoral studies
CRCHUM, Hôpital Notre-Dame, Institut du Cancer de Montreal
Departement de Biologie moléculaire, Université de Montreal
Supervisor : Dr Richard Bertrand

Postdoctoral studies
Department of Radiation Oncology, School of Medicine
Stanford, University
Supervisor: Dr Amato J. Giaccia

Doctorate in biochemistry (PhD)
Laboratoire de Médecine Moléculaire,
Université du Québec à Montréal (UQAM),
Supervisor: Dr Richard Béliveau

Master in chemistry (Biochemistry) (M.Sc)
Université du Québec à Montréal
Supervisor: Dr Diana A. Averill-Bates

Bachelor in biochemistry (B.Sc)
Université du Québec à Montréal

Funding :


Canadian Institutes for Health Research

Cancer Research Society

KRESCENT New Investigator

NB Health Research Foundation

NB Innovation Foundation

Dr Sandra Turcotte is Assistant Professor at the Université de Moncton and Researcher in Residency at the Atlantic Cancer Research Institute. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal. Dr Turcotte joined the Université de Moncton and ACRI in 2011 with a Research Chair from the Canadian Cancer Society New Brunswick. She is also recipient of a KRESCENT (Kidney Research Scientist Core Education and National Training program) New Investigator award (2012-2015).

Dr Turcotte is member of professional organization such as the Canadian Society of Nephrology and different associations and network such as the Beatrice Hunter Cancer Research Institute and the Kidney Cancer Research Network of Canada. She is also active in grant and scientific journal reviews, and teaching activities. She developed collaborations with national provincial researchers including some of her colleagues at the Université and ACRI.

Research Interests:

Kidney Cancer, clear cell Renal Cell Carinoma
Targeted therapy, synthetic lethality
Autophagy, lysosome
Translational research

Dr Turcotte's research interests focus on kidney cancer to develop targeted therapy based on synthetic lethality. Her studies identify a small molecule that target the loss of the von Hippel-Lindau (VHL) tumor suppressor gene by inducing autophagy. Her laboratory uses a variety of methods from genomic to metabolomic to study the role of autophagy in renal cancer cells. This work aim to transfer knowledge form laboratory bench to bedside to treat patient with kidney cancer.

Follow Us

Archived Articles

Atlantic Cancer Research Institute 
Pavillon Hôtel-Dieu
35, Providence Street
Moncton, NB E1C 8X3 Canada

Tel.: 506-862-7512
Fax.: 506-862-7571

Cover page
Our annual report
Download PDF bullet blanc

The Atlantic Cancer Research Institute

 (ACRI) is a non-profit organization founded in late 1998 and housed at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. Thanks to its unique expertise, ACRI has become a true centre of excellence in cancer research.


logo vitalite2020web 

Our Partners

 logo_vitalite.pnglogo_umoncton.pnglogo chudumontlogo unb logo soricimedlogo ccsCRS logoNBHRF logoMerck Logo.svg